Illinois Municipal Retirement Fund reduced its stake in Solventum Corporation (NYSE:SOLV – Free Report) by 34.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,853 shares of the company’s stock after selling 6,856 shares during the period. Illinois Municipal Retirement Fund’s holdings in Solventum were worth $1,133,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in SOLV. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in Solventum in the second quarter valued at about $150,066,000. Bank of America Corp DE grew its position in shares of Solventum by 0.6% during the 1st quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock worth $93,561,000 after buying an additional 9,083 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Solventum during the 2nd quarter worth about $61,460,000. Dimensional Fund Advisors LP increased its stake in shares of Solventum by 44.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock valued at $50,576,000 after acquiring an additional 236,659 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Solventum by 36.9% in the 1st quarter. KBC Group NV now owns 632,833 shares of the company’s stock valued at $41,324,000 after acquiring an additional 170,416 shares during the last quarter.
Solventum Trading Down 2.7%
SOLV opened at $86.23 on Wednesday. The stock has a market capitalization of $14.64 billion, a P/E ratio of 96.89, a P/E/G ratio of 1.26 and a beta of 0.69. The company has a current ratio of 1.03, a quick ratio of 0.72 and a debt-to-equity ratio of 0.99. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $94.16. The firm’s fifty day simple moving average is $87.39 and its 200 day simple moving average is $79.06.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Stifel Nicolaus increased their price target on shares of Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. BTIG Research reaffirmed a “buy” rating on shares of Solventum in a research note on Friday, November 6th. Jefferies Financial Group reiterated a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Benchmark reiterated a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Finally, UBS Group lifted their price target on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and an average price target of $90.27.
View Our Latest Stock Report on Solventum
About Solventum
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
See Also
- Five stocks we like better than Solventum
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
